Enlivex Therapeutics

Company Overview

Snapshot

Founded in September 2005 by Prof. Dror Mevorach, Enlivex Therapeutics operates with 11–50 employees. The company has raised a total of $286.9 million across 11 funding rounds from 5 investors. In November 2025, Enlivex Therapeutics raised $212 million, demonstrating significant investor confidence in its macrophage reprogramming cell therapies.

Business overview

Enlivex Therapeutics is a clinical-stage company specializing in macrophage reprogramming. It focuses on developing and commercializing a drug pipeline for various life-threatening diseases, including solid cancers, sepsis, and COVID-19. The company's flagship product candidate, Allocetra, is designed to reprogram diseased macrophages and has shown positive safety, tolerability, and efficacy in clinical trials for sepsis and COVID-19 patients. Enlivex operates within the Health Tech & Life Sciences sector, specifically targeting pharmaceuticals and biotechnology markets.

Strategic signal

In November 2025, Enlivex Therapeutics announced positive 6-month topline data for Allocetra in patients with moderate to severe knee osteoarthritis, demonstrating durable and persistent pain reduction and improved function. This clinical advancement signals the potential for Allocetra to address a significant unmet medical need in osteoarthritis, validating the company's macrophage reprogramming platform and expanding its therapeutic pipeline beyond acute inflammatory conditions.

Company Intelligence Q&A

What was a significant recent financial event for Enlivex Therapeutics?

In November 2025, Enlivex Therapeutics raised $212 million in a PIPE funding round.

What was a key clinical development for Allocetra in late 2025?

In November 2025, Enlivex announced positive 6-month topline data for Allocetra, demonstrating durable pain reduction and improved function in patients with moderate to severe knee osteoarthritis.

Did Enlivex Therapeutics receive any patent allowances recently?

In October 2024, Enlivex received a Notice of Allowance for a Japanese patent application covering the use of Allocetra in patients with osteoarthritis. Additionally, in September 2025, a new patent application covering the use of Allocetra in osteoarthritis patients was issued.

What was a notable corporate governance change for Enlivex Therapeutics in late 2025?

In November 2025, Enlivex Therapeutics announced the appointment of Mr. Matteo Renzi, former Prime Minister of Italy, to its board of directors.

What regulatory authorization did Enlivex Therapeutics receive in September 2024?

In September 2024, Enlivex Therapeutics received authorization from the Danish Medicines Agency to initiate the Phase II stage of its Phase I/II trial of Allocetra in patients with moderate to severe knee osteoarthritis.